Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TGM2 | P21980 | 8/20 | 0.39 |
| ▸ | F13A1 | P00488 | 5/20 | 0.39 |
| ▸ | TGM1 | P22735 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296315 | 0.88 | SMN1; SMN2 (0.41) | POLBSMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL3297889 | 0.87 | POLB (0.36) | POLBSMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL3303151 | 0.76 | CYP2C9 (0.44) | POLBSMN1; SMN2PKMALDH1A1GAA | |
| SCHEMBL3568010 | 0.73 | PTGDR2 (0.47) | ALDH1A1 | |
| SCHEMBL2656888 | 0.72 | POLB (0.59) | POLBSMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL2770749 | 0.71 | PTGDR2 (0.42) | SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL2771887 | 0.71 | PTGDR2 (0.47) | POLBSMN1; SMN2PKML3MBTL1ALDH1A1 | |
| SCHEMBL2769893 | 0.69 | PTGDR2 (0.44) | SMN1; SMN2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL15232086 | 0.67 | TGM2 (0.62) | POLBSMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL18498875 | 0.66 | TGM2 (0.53) | TGM2F13A1TGM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | HRH2, HRH4, HRH1 | POLB 4362/4885SMN1; SMN2 4193/4885TGM2 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.